Bausch + Lomb stock hits 52-week high at $17.87

Bausch + Lomb, a leading global eye health company, saw its stock reach a 52-week high of $17.87 on the New York Stock Exchange on October 15, 2023, driven by strong quarterly earnings and positive market sentiment toward healthcare stocks. The eye care specialist, known for its contact lenses, surgical products, and eye vitamins, has experienced steady growth as consumers increasingly prioritize eye health post-pandemic. Analysts attribute the surge to successful product launches in the Asian market and strategic partnerships with ophthalmology clinics worldwide. Market observers note that Bausch + Lomb's expansion into emerging markets has particularly boosted investor confidence, with revenue from China and India growing by 23% year-over-year. The company's recent acquisition of a smaller competitor specializing in dry eye treatments has also positioned it to capture a larger share of the lucrative ophthalmic market. Financial reports indicate that Bausch + Lomb exceeded Wall Street expectations with a 15% increase in quarterly revenue, reaching $850 million, with the stock now rising 32% since the beginning of the year, outperforming many healthcare sector peers.